Search: onr:"swepub:oai:DiVA.org:uu-433904" >
Therapeutic drug mo...
Therapeutic drug monitoring of anti-tumor necrosis factor agents : lessons learned and remaining issues
-
- Wang, Zhigang (author)
- Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium.
-
- Dreesen, Erwin (author)
- Uppsala universitet,Institutionen för farmaci,Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium.;Uppsala Univ, Dept Pharm, Uppsala, Sweden.
-
Katholieke Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Leuven, Belgium Institutionen för farmaci (creator_code:org_t)
- OXFORD ENGLAND : Elsevier BV, 2020
- 2020
- English.
-
In: Current opinion in pharmacology (Print). - OXFORD ENGLAND : Elsevier BV. - 1471-4892 .- 1471-4973. ; 55, s. 53-59
- Related links:
-
https://doi.org/10.1...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Therapeutic drug monitoring (TDM) of anti-tumor necrosis factor agents (anti-TNFs) has received extensive attention due to its potential for improving treatment outcomes in patients with inflammatory bowel diseases. However, the benefits of applying TDM in clinical practice remain largely unclear due to a lack of evidence from the available prospective randomized controlled studies. The questionable evidence for TDM obtained in these studies can be caused by several design suboptimalities, including long turnaround times of sample analysis, use of inappropriate exposure targets, insufficiently precise algorithms for dose optimization, and inapt trial designs. In future studies, model-informed precision dosing in combination with rapid testing methods is recommended to maximize the potential of TDM of anti-TNFs.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmakologi och toxikologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmacology and Toxicology (hsv//eng)
Keyword
- INFLAMMATORY-BOWEL-DISEASE; POINT-OF-CARE; EVIDENCE-BASED CONSENSUS; CROHNS-DISEASE; SERUM INFLIXIMAB; DOSE ADJUSTMENT; MANAGEMENT; ASSOCIATION; ANTIBODIES; DIAGNOSIS
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
To the university's database